Indivior Pharmaceuticals, Inc. - 8-K Filing
Indivior Pharmaceuticals completed its merger with Supernus, renaming itself Supernus, Inc. and securing a $650 million credit facility. (Items: 1.01 Entry into a Material Definitive Agreement, 2.01 Completion of Acquisition or Disposition of Assets, 5.03 below, “Indivior Shares”), 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant)
Tickers: $INDV